The search strategy targeted studies involving GLP-1 receptor agonists (e.g., exenatide, liraglutide, dulaglutide, lixisenatide, benaglutide, loxenatide, semaglutide) and multi-target receptor agonists (e.g., tirzepatide), focusing on gastrointestinal adverse events (e.g., nausea, vomiting, diarrhea, constipation, dyspepsia, and reduced appetite) in patients with type 2 diabetes mellitus (T2DM) (Supplementary Material)
Glutathione-Related Enzymes The destructive effects of elevated ROS levels in plants are controlled by different scavenging enzymatic and non-enzymatic mechanisms
The medication works by mimicking the action of the naturally occurring hormone GLP-1, which regulates appetite and food intake by acting on receptors in the brain, pancreas, and gastrointestinal tract
As I mentioned, there are a lot of studies of these drugs, but very few where they are tested head-to-head